{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,22]],"date-time":"2026-08-22T03:23:41Z","timestamp":1787369021319,"version":"build-2736575974"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,8,21]]},"DOI":"10.7759\/cureus.114952","type":"journal-article","created":{"date-parts":[[2026,8,22]],"date-time":"2026-08-22T03:02:26Z","timestamp":1787367746000},"source":"Crossref","is-referenced-by-count":0,"title":["When Literature Priors Are Removed: Clinical Rank Shifts and Transancestral Stability in Antipsychotic Low-Density Lipoprotein (LDL)-Risk Modelling"],"prefix":"10.7759","author":[{"given":"Ngo","family":"Cheung","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hoi-Ki","family":"Cheung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yee-Wah","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yolanda Yuen-Ching","family":"Tsang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0094112","article-title":"Almost all antipsychotics result in weight gain: a meta-analysis","volume":"9","author":"Bak M","year":"2014","unstructured":"Bak M, Fransen A, Janssen J, van Os J, Drukker M. Almost all antipsychotics result in weight gain: a meta-analysis. PLoS One. 2014, 9:e94112. 10.1371\/journal.pone.0094112","journal-title":"PLoS One"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1017\/S0033291721000180","article-title":"Association between the glyco-metabolic adverse effects of antipsychotic drugs and their chemical and pharmacological profile: a network meta-analysis and regression","volume":"52","author":"Carnovale C","year":"2022","unstructured":"Carnovale C, Lucenteforte E, Battini V, et al.. Association between the glyco-metabolic adverse effects of antipsychotic drugs and their chemical and pharmacological profile: a network meta-analysis and regression. Psychol Med. 2022, 52:3508-20. 10.1017\/S0033291721000180","journal-title":"Psychol Med"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(13)60733-3","article-title":"Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis","volume":"382","author":"Leucht S","year":"2013","unstructured":"Leucht S, Cipriani A, Spineli L, et al.. Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. Lancet. 2013, 382:951-962. 10.1016\/S0140-6736(13)60733-3","journal-title":"Lancet"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/S2215-0366(19)30416-X","article-title":"Comparative effects of 18 antipsychotics on metabolic function in patients with schizophrenia, predictors of metabolic dysregulation, and association with psychopathology: a systematic review and network meta-analysis","volume":"7","author":"Pillinger T","year":"2020","unstructured":"Pillinger T, McCutcheon RA, Vano L, et al.. Comparative effects of 18 antipsychotics on metabolic function in patients with schizophrenia, predictors of metabolic dysregulation, and association with psychopathology: a systematic review and network meta-analysis. Lancet Psychiatry. 2020, 7:64-77. 10.1016\/S2215-0366(19)30416-X","journal-title":"Lancet Psychiatry"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/j.schres.2010.07.012","article-title":"Head-to-head comparisons of metabolic side effects of second generation antipsychotics in the treatment of schizophrenia: a systematic review and meta-analysis","volume":"123","author":"Rummel-Kluge C","year":"2010","unstructured":"Rummel-Kluge C, Komossa K, Schwarz S, et al.. Head-to-head comparisons of metabolic side effects of second generation antipsychotics in the treatment of schizophrenia: a systematic review and meta-analysis. Schizophr Res. 2010, 123:225-33. 10.1016\/j.schres.2010.07.012","journal-title":"Schizophr Res"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.4088\/jcp.v65n0219","article-title":"Consensus development conference on antipsychotic drugs and obesity and diabetes","volume":"65","author":"American Diabetes Association; American Psychiatric Association; American Association of Clinical Endocrinologists; North American Association for the Study of Obesity","year":"2004","unstructured":"American Diabetes Association; American Psychiatric Association; American Association of Clinical Endocrinologists; North American Association for the Study of Obesity. Consensus development conference on antipsychotic drugs and obesity and diabetes. J Clin Psychiatry. 2004, 65:267-72. 10.4088\/jcp.v65n0219","journal-title":"J Clin Psychiatry"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1177\/0269881116645254","article-title":"BAP guidelines on the management of weight gain, metabolic disturbances and cardiovascular risk associated with psychosis and antipsychotic drug treatment","volume":"30","author":"Cooper SJ","year":"2016","unstructured":"Cooper SJ, Reynolds GP, Barnes T, et al.. BAP guidelines on the management of weight gain, metabolic disturbances and cardiovascular risk associated with psychosis and antipsychotic drug treatment. J Psychopharmacol. 2016, 30:717-48. 10.1177\/0269881116645254","journal-title":"J Psychopharmacol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1007\/s00213-004-1922-7","article-title":"Guidelines for prevention and treatment of adverse effects of antipsychotic drugs on glucose-insulin homeostasis and lipid metabolism","volume":"175","author":"Melkersson KI","year":"2004","unstructured":"Melkersson KI, Dahl ML, Hulting AL. Guidelines for prevention and treatment of adverse effects of antipsychotic drugs on glucose-insulin homeostasis and lipid metabolism. Psychopharmacology (Berl). 2004, 175:1-6. 10.1007\/s00213-004-1922-7","journal-title":"Psychopharmacology (Berl)"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1038\/sj.npp.1300027","article-title":"H1-histamine receptor affinity predicts short-term weight gain for typical and atypical antipsychotic drugs","volume":"28","author":"Kroeze WK","year":"2003","unstructured":"Kroeze WK, Hufeisen SJ, Popadak BA, et al.. H1-histamine receptor affinity predicts short-term weight gain for typical and atypical antipsychotic drugs. Neuropsychopharmacology. 2003, 28:519-26. 10.1038\/sj.npp.1300027","journal-title":"Neuropsychopharmacology"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/j.molmed.2010.10.010","article-title":"Antipsychotic drugs and obesity","volume":"17","author":"Correll CU","year":"2011","unstructured":"Correll CU, Lencz T, Malhotra AK. Antipsychotic drugs and obesity. Trends Mol Med. 2011, 17:97-107. 10.1016\/j.molmed.2010.10.010","journal-title":"Trends Mol Med"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1038\/nrendo.2011.156","article-title":"Metabolic and cardiovascular adverse effects associated with antipsychotic drugs","volume":"8","author":"De Hert M","year":"2011","unstructured":"De Hert M, Detraux J, van Winkel R, Yu W, Correll CU. Metabolic and cardiovascular adverse effects associated with antipsychotic drugs. Nat Rev Endocrinol. 2011, 8:114-26. 10.1038\/nrendo.2011.156","journal-title":"Nat Rev Endocrinol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.2174\/1570159X15666170630163616","article-title":"Antipsychotic drugs: from receptor-binding profiles to metabolic side effects","volume":"16","author":"Siafis S","year":"2018","unstructured":"Siafis S, Tzachanis D, Samara M, Papazisis G. Antipsychotic drugs: from receptor-binding profiles to metabolic side effects. Curr Neuropharmacol. 2018, 16:1210-23. 10.2174\/1570159X15666170630163616","journal-title":"Curr Neuropharmacol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1177\/107385840000600408","article-title":"The multiplicity of serotonin receptors: uselessly diverse molecules or an embarrassment of riches?","volume":"6","author":"Roth BL","year":"2000","unstructured":"Roth BL, Kroeze WK, Patel S, Lopez E. The multiplicity of serotonin receptors: uselessly diverse molecules or an embarrassment of riches?. The Neuroscientist. 2000, 6:252-262. 10.1177\/107385840000600408","journal-title":"The Neuroscientist"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-021-04064-3","article-title":"The power of genetic diversity in genome-wide association studies of lipids","volume":"600","author":"Graham SE","year":"2021","unstructured":"Graham SE, Clarke SL, Wu KH, et al.. The power of genetic diversity in genome-wide association studies of lipids. Nature. 2021, 600:675-9. 10.1038\/s41586-021-04064-3","journal-title":"Nature"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1016\/j.xgen.2022.100180","article-title":"Best practices for multi-ancestry, meta-analytic transcriptome-wide association studies: lessons from the Global Biobank Meta-analysis Initiative","volume":"2","author":"Bhattacharya A","year":"2022","unstructured":"Bhattacharya A, Hirbo JB, Zhou D, et al.. Best practices for multi-ancestry, meta-analytic transcriptome-wide association studies: lessons from the Global Biobank Meta-analysis Initiative. Cell Genom. 2022, 2:10.1016\/j.xgen.2022.100180","journal-title":"Cell Genom"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1002\/gepi.22290","article-title":"Investigation of prediction accuracy and the impact of sample size, ancestry, and tissue in transcriptome-wide association studies","volume":"44","author":"Fryett JJ","year":"2020","unstructured":"Fryett JJ, Morris AP, Cordell HJ. Investigation of prediction accuracy and the impact of sample size, ancestry, and tissue in transcriptome-wide association studies. Genet Epidemiol. 2020, 44:425-41. 10.1002\/gepi.22290","journal-title":"Genet Epidemiol"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1038\/s41588-019-0367-1","article-title":"Probabilistic fine-mapping of transcriptome-wide association studies","volume":"51","author":"Mancuso N","year":"2019","unstructured":"Mancuso N, Freund MK, Johnson R, Shi H, Kichaev G, Gusev A, Pasaniuc B. Probabilistic fine-mapping of transcriptome-wide association studies. Nat Genet. 2019, 51:675-82. 10.1038\/s41588-019-0367-1","journal-title":"Nat Genet"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1038\/s41588-019-0385-z","article-title":"Opportunities and challenges for transcriptome-wide association studies","volume":"51","author":"Wainberg M","year":"2019","unstructured":"Wainberg M, Sinnott-Armstrong N, Mancuso N, et al.. Opportunities and challenges for transcriptome-wide association studies. Nat Genet. 2019, 51:592-9. 10.1038\/s41588-019-0385-z","journal-title":"Nat Genet"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.6084\/m9.figshare.32993975.v1","article-title":"Systematic comparison of four TWAS scaling methods within an integrated Ki-DDD-TWAS pipeline for antipsychotic metabolic risk assessment","author":"Cheung N","year":"2026","unstructured":"Cheung N, Cheung HK, Yu YW, Tsang YCY. Systematic comparison of four TWAS scaling methods within an integrated Ki-DDD-TWAS pipeline for antipsychotic metabolic risk assessment. figshare. 2026, 10.6084\/m9.figshare.32993975.v1","journal-title":"figshare"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.6084\/m9.figshare.33028355.v1","article-title":"Beyond prior weights: receptor contribution reallocation and hypothesis-generating TWAS candidates in antipsychotic metabolic-risk modelling","author":"Cheung N","year":"2026","unstructured":"Cheung N, Cheung HK, Yu YW, Tsang YCY. Beyond prior weights: receptor contribution reallocation and hypothesis-generating TWAS candidates in antipsychotic metabolic-risk modelling. figshare. 2026, 10.6084\/m9.figshare.33028355.v1","journal-title":"figshare"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.6084\/m9.figshare.33028472.v1","article-title":"Receptor-prior sensitivity reveals transancestral stability and clinical discordance in HDL-related antipsychotic metabolic-risk ranking: insights from an integrated Ki-DDD-TWAS pipeline","author":"Cheung N","year":"2026","unstructured":"Cheung N, Cheung HK, Yu YW, Tsang YCY. Receptor-prior sensitivity reveals transancestral stability and clinical discordance in HDL-related antipsychotic metabolic-risk ranking: insights from an integrated Ki-DDD-TWAS pipeline. figshare. 2026, 10.6084\/m9.figshare.33028472.v1","journal-title":"figshare"},{"key":"ref22","unstructured":"ATC\/DDD Index 2026. (2026). Accessed. July 20, 2026: https:\/\/atcddd.fhi.no\/atc_ddd_index\/."},{"key":"ref23","unstructured":"KiDatabase_2026- 06-22.csv. Internal curated ligand-receptor affinity dataset used in the present analysis. (2026). https:\/\/github.com\/cheungngo\/080JvG-Clinical-Rank-Shifts-and-Transancestral-Stability-in-Antipsychotic-LDL-Risk-Model...."},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1042\/CS20190579","article-title":"A compendium of G-protein-coupled receptors and cyclic nucleotide regulation of adipose tissue metabolism and energy expenditure","volume":"134","author":"Ceddia RP","year":"2020","unstructured":"Ceddia RP, Collins S. A compendium of G-protein-coupled receptors and cyclic nucleotide regulation of adipose tissue metabolism and energy expenditure. Clin Sci (Lond). 2020, 134:473-512. 10.1042\/CS20190579","journal-title":"Clin Sci (Lond)"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgz298","article-title":"Beta-1 and not beta-3 adrenergic receptors may be the primary regulator of human brown adipocyte metabolism","volume":"105","author":"Riis-Vestergaard MJ","year":"2020","unstructured":"Riis-Vestergaard MJ, Richelsen B, Bruun JM, Li W, Hansen JB, Pedersen SB. Beta-1 and not beta-3 adrenergic receptors may be the primary regulator of human brown adipocyte metabolism. J Clin Endocrinol Metab. 2020, 105:10.1210\/clinem\/dgz298","journal-title":"J Clin Endocrinol Metab"},{"key":"ref26","unstructured":"080JvG(rank_changes_without_w)_TWAS_LDL_Risk_x_Antipsychotics_Ki.ipynb. (2026). Accessed. August 17, 2026: https:\/\/github.com\/cheungngo\/080JvG-Clinical-Rank-Shifts-and-Transancestral-Stability-in-Antipsychotic-LDL-Risk-Model...."}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/519380-when-literature-priors-are-removed-clinical-rank-shifts-and-transancestral-stability-in-antipsychotic-low-density-lipoprotein-ldl-risk-modelling","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,22]],"date-time":"2026-08-22T03:02:30Z","timestamp":1787367750000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/519380-when-literature-priors-are-removed-clinical-rank-shifts-and-transancestral-stability-in-antipsychotic-low-density-lipoprotein-ldl-risk-modelling"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,21]]},"references-count":26,"URL":"https:\/\/doi.org\/10.7759\/cureus.114952","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8,21]]}}}